☆ 4.7 Article

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis

JAMA NETWORK OPEN (2023)

Related references

Note: Only part of the references are listed.

Article Virology

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual

Peter J. Halfmann et al.

Summary: Prolonged infections in immunocompromised individuals can lead to the emergence of novel SARS-CoV-2 variants, as seen in a 486-day case of infection. Treatment with the monoclonal antibody Bamlanivimab resulted in the acquisition of resistance by the virus, through the emergence of the Spike amino acid variant E484T. This highlights the importance of studying prolonged infections in immunocompromised individuals for understanding the evolution of new variants.

VIRUS EVOLUTION (2023)

Add to Collection

Letter Hematology

Understanding the parameters guiding the best practice for treating B-cell-depleted patients with COVID-19 convalescent plasma therapy

David Gachoud et al.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Article Immunology

Prolonged COVID-19 Infection in a Patient with Newly Diagnosed HIV/AIDS

Tom Ketels et al.

Summary: Our case demonstrates a prolonged COVID-19 infection in a patient with undiagnosed HIV with severely impaired cellular immunity.

AIDS RESEARCH AND HUMAN RETROVIRUSES (2022)

Add to Collection

Article Immunology

Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency

Julia Lang-Meli et al.

Summary: Convalescent plasma treatment in patients with primary antibody deficiency may be beneficial, reducing viral load and improving clinical symptoms even weeks after infection. The treatment appears to be safe and effective, with PCR follow-up recommended for patients with persistent viral shedding and early retreatment considered when necessary.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis

Thomas Hueso et al.

Summary: Patients with hematological malignancy and COVID-19 have a high mortality rate. COVID-19 convalescent plasma (CCP) therapy shows promise in transferring neutralizing antibodies to enhance the immune response. In patients with B-cell lymphoid disease who have received anti-CD20 therapy, CCP treatment is associated with a lower mortality rate.

LEUKEMIA (2022)

Add to Collection

Review Infectious Diseases

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature

Marcial Delgado-Fernandez et al.

Summary: This article discusses the use of COVID-19 convalescent plasma (CCP) in patients with humoral immunodeficiency. The study suggests that CCP can improve clinical symptoms and shorten the duration of the disease for patients with congenital primary immunodeficiency or those on treatment with anti CD20 antibodies.

ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA (2022)

Add to Collection

Letter Medicine, General & Internal

Vax-Plasma in Patients With Refractory COVID-19

Eloy E. Ordaya et al.

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Letter Immunology

Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis

Marina Pontello Cristelli et al.

TRANSPLANTATION (2022)

Add to Collection

Article Immunology

COVID-19 in Recent Lung Transplant Recipients: Clinical Outcomes and Management Strategies

Julia Zimmermann et al.

Summary: This study describes outcomes and potential management strategies for early COVID-19 infection in lung transplant recipients, revealing that COVID-19 in these patients does not appear to cause milder disease. Immunosuppression may delay antibody formation and lead to premature loss.

TRANSPLANTATION PROCEEDINGS (2022)

Add to Collection

Article Oncology

Prolonged COVID-19 infection in a child with lymphoblastic non-Hodgkin lymphoma: which is the best management?

Giovanna Gattuso et al.

Summary: A case of an 11-year-old boy with T-cell lymphoblastic lymphoma undergoing treatment for COVID-19 without significant changes to oncologic therapy, resulting in a positive antibody titer after receiving COVID-19 convalescent plasma.

TUMORI JOURNAL (2022)

Add to Collection

Article Virology

Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies

Aude Jary et al.

Summary: This study explored the molecular evolution of the spike gene in COVID-19 patients after receiving antibody treatment. Some patients acquired mutations during the follow-up period, with one mutation having no clinical impact and another mutation leading to fatal outcomes. It is recommended to carefully monitor the virology of patients treated with antibodies, especially those who are immunosuppressed.

VIRUSES-BASEL (2022)

Add to Collection

Article Infectious Diseases

Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases

Oskar Ljungquist et al.

Summary: This study described the clinical and virological treatment outcomes of a group of severely immunosuppressed patients with COVID-19 who received convalescent plasma treatment. Results showed that some patients improved clinically after CCP treatment, but caution should be taken in interpreting the results due to limitations in the study design. Prospective, randomized trials are needed for further investigation.

INFECTIOUS DISEASES (2022)

Add to Collection

Letter Public, Environmental & Occupational Health

Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient

Carly M. Hughes et al.

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Pharmacokinetics of high-titer anti- SARS-CoV-2 human convalescent plasma in high-risk children

Oren Gordon et al.

Summary: In this study, the kinetics of antibodies transferred via COVID-19 convalescent plasma in high-risk children were evaluated. The results showed that convalescent plasma transfusion was safe and had expected antibody kinetics in high-risk children, and it had a certain neutralization capacity to prevent severe disease.

JCI INSIGHT (2022)

Add to Collection

Article Transplantation

Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics

Afrah S. Sait et al.

Summary: This study investigated the use of newer COVID-19 therapies in solid organ transplant recipients and found that these treatments did not have a detrimental effect on allograft function and infectious complications were comparable.

TRANSPLANTATION DIRECT (2022)

Add to Collection

Article Clinical Neurology

Acute Cerebellitis and Myeloradiculitis Associated With SARS-CoV-2 Infection in Common Variable Immunodeficiency-A Case Report

Hernan Nicolas Lemus et al.

Summary: The case reported a CVID patient with SARS-CoV-2 infection presenting isolated neurological symptoms, who subsequently improved following treatment with convalescent plasma. It indicates that convalescent plasma may be effective in treating COVID-19 in patients with primary immunodeficiency.

NEUROHOSPITALIST (2022)

Add to Collection

Editorial Material Cardiac & Cardiovascular Systems

Heart Transplantation Complicated by COVID-19 Infection

Thomas Martens et al.

Summary: This is a case report on the impact of COVID-19 infection on heart transplantation. It presents the diagnosis of a 60-year-old male patient with COVID-19 infection six days after transplantation. The patient's clinical course consisted of two phases, with initial mild respiratory symptoms treated with appropriate measures and subsequent clinical deterioration necessitating the use of convalescent plasma, leading to a satisfactory response.

ANNALS OF THORACIC SURGERY (2022)

Add to Collection

Article Immunology

Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients

Arvind Gharbharan et al.

Summary: In this study, twenty-five B-cell-depleted patients diagnosed with COVID-19, most of whom had received anti-CD19/20 therapy, were treated with convalescent plasma containing high neutralizing antibody titers. 84% of the patients recovered, suggesting the potential therapeutic effects of this treatment in this specific population.

CLINICAL INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Specific T-cell responses for guiding treatment with convalescent plasma in severe COVID-19 and humoral immunodeficiency: a case report

Katarina Nystrom et al.

Summary: This case report highlights the importance of evaluating T-cell responses in COVID-19 patients with humoral immunodeficiencies. It demonstrates that hyperinflammation can occur in the absence of a humoral anti-viral response and that the presence of SARS-CoV-2 specific T cells is crucial for viral clearance.

BMC INFECTIOUS DISEASES (2022)

Add to Collection

Article Immunology

Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations

Daniele Focosi et al.

Summary: Convalescent plasma containing polyclonal anti-SARS-CoV-2 immunoglobulins has shown promising results in immunocompromised patients, especially when administered at high neutralizing antibody titers. Genetic monitoring of refractory patients is recommended to prevent the emergence of SARS-CoV-2 variants within the host.

EXPERT REVIEW OF VACCINES (2022)

Add to Collection

Review Microbiology

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes

Daniele Focosi et al.

Summary: Convalescent plasma (CP) is a frontline treatment in epidemics due to its immediate availability. The COVID-19 pandemic provided an opportunity to study the mechanisms, safety, and efficacy of CP using evidence-based medicine. However, studies have reported highly variable efficacy results for COVID-19 CP (CCP), leading to uncertainty.

CLINICAL MICROBIOLOGY REVIEWS (2022)

Add to Collection

Article Infectious Diseases

Remdesivir in Coronavirus Disease 2019 patients treated with anti-CD20 monoclonal antibodies: a case series

Susanne Rufenacht et al.

Summary: This study aimed to investigate the effectiveness of remdesivir treatment in COVID-19 patients on anti-CD20 therapy. The results showed that the majority of patients did not experience clinical relapse during one year of follow-up, suggesting a potential benefit of antiviral therapy. However, the lack of a control group is a significant limitation of this study design.

INFECTION (2022)

Add to Collection

Review Oncology

Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European Conference on Infections in Leukaemia (ECIL 9)

Simone Cesaro et al.

Summary: SARS-CoV-2 infection can lead to severe outcomes in immunocompromised hematological patients, with high mortality rates observed. Treatment strategies focus on controlling viral replication and inflammation. However, the effectiveness and benefits of preventive and therapeutic measures in hematological patients require further investigation.

LEUKEMIA (2022)

Add to Collection

Article Immunology

SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity

Sophie Steiner et al.

Summary: This study reports clinical and immunological findings in PAD patients with severe/fatal COVID-19 and undetectable humoral immune response to SARS-CoV-2. Robust T cell response was observed in all examined PAD patients, indicating the importance of T cell immunity in COVID-19.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

Persistence of SARS-CoV-2 Infection in Severely Immunocompromised Patients With Complete Remission B-Cell Lymphoma and Anti-CD20 Monoclonal Antibody Therapy: A Case Report of Two Cases

Carlos Martinez-Chinchilla et al.

Summary: Immunosuppressant patients, such as those with hematological malignancies, have a higher risk of SARS-CoV-2 infection. This study presents two cases of B-cell lymphoma patients treated with rituximab who experienced recurrent flares of COVID-19 after acute infection. These cases highlight the unresolved issue of COVID-19 in immunosuppressant patients.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Hematology

Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report

Martina Di Palma et al.

Summary: This article describes the clinical history of a patient with concomitant acute lymphoblastic leukemia (ALL) and COVID-19 infection. The patient developed Sars-CoV2 prior to treatment initiation, but was asymptomatic for COVID-19. Despite respiratory findings worsening during treatment, the patient achieved complete hematologic remission without completing the full treatment cycle and spontaneously developed anti-Sars-CoV-2 antibodies. After COVID-19 recovery, the patient underwent transplantation and achieved complete remission.

MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2022)

Add to Collection

Review Medicine, General & Internal

Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer A Systematic Review and Meta-analysis

Emma Khoury et al.

Summary: The study found that patients with cancer and SARS-CoV-2 infection had a higher risk of death compared to those without cancer. Younger age, lung cancer, and hematologic cancer were identified as risk factors associated with poor outcomes from COVID-19.

JAMA NETWORK OPEN (2022)

Add to Collection

Article Hematology

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Maggie Li et al.

Summary: The COVID-19 convalescent plasma (CCP) with high antibody levels effectively reduces hospitalization for immunocompetent outpatient. The study found that CCP can effectively neutralize the three variants.

BLOOD ADVANCES (2022)

Add to Collection

Article Hematology

COVID-19-Associated Pneumonia in a B-Cell-Depleted Patient With Non-Hodgkin Lymphoma: Recovery With Hyperimmune Plasma

Daniele Colombo et al.

Summary: Patients with impaired immune function and hematological malignancies may have severe and prolonged course of COVID-19. Lack of B lymphocytes and impaired antibody production may contribute to the poor prognosis. The administration of convalescent hyperimmune plasma may aid in clinical recovery.

JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Hematology

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Ferenc Magyari et al.

Summary: In this study, the combination of remdesivir and convalescent plasma therapy was found to be efficient and safe for the treatment of COVID-19 in patients with hematological malignancies and B-cell lymphopenia. This combined treatment reduced the need for oxygen support, length of hospital stay, and viral positivity.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma

Lise J. Estcourt et al.

Summary: This article introduces the therapeutic application of convalescent plasma for COVID-19 patients and provides corresponding clinical practice guidelines. The guidelines include recommendations for the use of convalescent plasma for outpatients and inpatients, as well as for prophylactic application. For high-risk patients, it is recommended to transfuse convalescent plasma in addition to standard care, while for hospitalized patients without detectable SARS-CoV-2 antibodies, it is suggested to transfuse convalescent plasma in addition to standard care.

ANNALS OF INTERNAL MEDICINE (2022)

Add to Collection

Review Infectious Diseases

Monoclonal antibody therapies against SARS-CoV-2

Daniele Focosi et al.

Summary: This paper reviews the use of monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 in the ongoing COVID-19 pandemic and discusses their therapeutic effects, structural classification, immune escape, and limitations. It also explores the impact of the Omicron variant on treatment strategies and potential future developments for improved outcomes.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Virology

Variant of Concern-Matched COVID-19 Convalescent Plasma Usage in Seronegative Hospitalized Patients

Massimo Franchini et al.

Summary: COVID-19 convalescent plasma (CCP) has been the only available specific anti-viral therapy against SARS-CoV-2 for over a year. While its usage decreased with the availability of anti-spike monoclonal antibodies (mAbs), the emergence of new variants of concern has renewed interest in CCP, especially in seronegative immunocompetent patients and immunocompromised patients. This study presents the experience of an Italian hospital in collecting and transfusing CCP to immunocompromised patients hospitalized for severe COVID-19.

VIRUSES-BASEL (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

SARS-CoV-2 evolution in a patient with secondary B-cell immunodeficiency: A clinical case

Olgo A. Mukhina et al.

Summary: The article discusses the case of a patient with long-term SARS-CoV-2 infection and secondary immunodeficiency. The analysis shows a mutation in the S-protein that may affect its binding ability to cellular receptors. Treatment with a COVID-19-globulin preparation resulted in rapid improvement, elimination of the virus, and passive immunization for at least 30 days.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2022)

Add to Collection

Article Biology

Clinical and Virological Response to Convalescent Plasma in a Chronic Lymphocytic Leukemia Patient with COVID-19 Pneumonia

Giovanni Belcari et al.

Summary: This case report demonstrates the successful treatment of COVID-19 pneumonia in an immunocompromised patient with chronic lymphocytic leukemia and venetoclax treatment using high-titer and large-volume convalescent plasma. This adds to the growing evidence of convalescent plasma efficacy in immunocompromised patients.

LIFE-BASEL (2022)

Add to Collection

Article Immunology

Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway

Alessandra D'Abramo et al.

Summary: This case series study describes the clinical characteristics and treatment outcomes of 21 COVID-19 patients receiving B-cell depletion therapy. Most patients achieved recovery through combined therapy including remdesivir, steroids, monoclonal antibodies, and/or hyper-immune convalescent plasma.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Oncology

Successful Use of COVID-19 Convalescent Plasma in a Patient Recently Treated for Follicular Lymphoma

Zachary Wright et al.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Editorial Material Immunology

Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019

Martin Martinot et al.

Summary: A 76-year-old female with post-rituximab B-cell immuno-deficiency and persistent SARS-CoV-2 viremia developed a mutation in RdRP (D484Y) following treatment with remdesivir, but was successfully cured after supplementation with convalescent plasma.

CLINICAL INFECTIOUS DISEASES (2021)

Add to Collection

Editorial Material Infectious Diseases

What is the optimal usage of coronavirus disease 2019 convalescent plasma donations? Comment

Daniele Focosi et al.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

Add to Collection

Article Allergy

Coronavirus disease 2019 in patients with inborn errors of immunity: An international study

Isabelle Meyts et al.

Summary: The study shows that patients with IEI exhibit varied responses to SARS-CoV-2 infection, with some requiring hospitalization and even intensive care, and a non-negligible mortality rate. In comparison to the general population, younger IEI patients may face a higher risk of severe illness and mortality.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient

Ji Hoon Baang et al.

Summary: This case illustrates challenges in managing immunocompromised hosts with chronic COVID-19, who may act as persistent shedders and sources of transmission. The patient's lack of seroconversion and prolonged course highlight the importance of humoral immunity in resolving viral infections.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Transplantation

Transplant of SARS-CoV-2-infected Living Donor Liver: Case Report

Michelle C. Nguyen et al.

Summary: This case report presents a successful living donor liver transplant where both the donor and recipient had excellent postoperative outcomes without viral transmission despite the donor having confirmed SARS-CoV-2 infection.

TRANSPLANTATION DIRECT (2021)

Add to Collection

Article Hematology

Convalescent plasma to aid in recovery of COVID-19 pneumonia in a child with acute lymphoblastic leukemia

Ravi Shankar et al.

Summary: Most children with COVID-19 have mild infections, but those with cancer are considered a high-risk group for all infections. Currently, there are no established treatment guidelines for severe COVID-19 in children, with treatment often guided by adult recommendations lacking evidence-based support.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

High-titre convalescent plasma therapy for an immunocompromised patient with systemic lupus erythematosus with protracted SARS-CoV-2 infection

Sara Moutinho-Pereira et al.

Summary: This case demonstrates that persistent SARS-CoV-2 infection in an immunocompromised patient may be reversed with appropriate treatment.

BMJ CASE REPORTS (2021)

Add to Collection

Letter Allergy

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

Hsi-en Ho et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Medicine, General & Internal

Evaluation of the relative virulence of novel SARS-CoV-2 variants: a retrospective cohort study in Ontario, Canada

David N. Fisman et al.

Summary: Research in Ontario, Canada, showed that new variants of concern (VOCs) of SARS-CoV-2 have higher risks of hospitalization, ICU admission, and death compared to non-VOC strains, with the Delta variant showing the most pronounced increase in risk.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2021)

Add to Collection

Article Oncology

Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies

Silvia Ferrari et al.

Summary: This study described the use of hyperimmune plasma therapy in immunocompromised patients with hematological disorders during the SARS-CoV-2 outbreak, showing positive outcomes such as clinical improvement, recovery, and viral clearance. While further research is needed, the results suggest a specific role for hyperimmune plasma therapy in hematological patients.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Letter Immunology

COVID-19 in Solid Organ Transplant Recipients: Observations From Connecticut

Heather L. Kutzler et al.

TRANSPLANTATION (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report

Jacek Jassem et al.

Summary: This study demonstrates that B-cell depleted patients may effectively respond to anti-SARS-CoV-2 treatment when NK and antigen-specific Tc cell response is induced, leading to viral clearance.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Immunology

SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency

Nicolai S. C. van Oers et al.

Summary: X-linked severe combined immunodeficiency (X-SCID) is a severe immune disorder caused by genetic mutations, with patients facing opportunistic infections. An infant with X-SCID contracted SARS-CoV-2 before receiving a stem cell transplant, but ultimately recovered after treatment.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Prolonged viral positivity induced recurrent coronavirus disease 2019 (COVID-19) pneumonia in patients receiving anti-CD20 monoclonal antibody treatment Case reports

Burak Deveci et al.

Summary: This study presents 4 cases of COVID-19 patients on anti-CD20 monoclonal antibody therapy with prolonged pneumonia. Despite receiving standard treatments including convalescent plasma, these patients continued to test positive for the virus and experienced prolonged pneumonia, indicating potential issues with the immune system's ability to mount an antibody response. Further investigations are needed to understand the underlying pathophysiology and potentially improve outcomes for patients in similar situations.

MEDICINE (2021)

Add to Collection

Article Infectious Diseases

Secondary hemophagocytic lymphohistiocytosis and severe liver injury induced by hepatic SARS-CoV-2 infection unmasking Wilson's disease: Balancing immunosuppression

Matthias Lubnow et al.

Summary: This case highlights the complexity of balancing immunosuppression to control hyperinflammation and prevent systemic SARS-CoV-2 dissemination during treatment.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Letter Immunology

A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma

Aled Iaboni et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Immunology

Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia

Emily McKemey et al.

JOURNAL OF CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Oncology

Severe clinical relapse in an immunocompromised host with persistent SARS-CoV-2 infection

Philipp A. Reuken et al.

LEUKEMIA (2021)

Add to Collection

Article Multidisciplinary Sciences

SARS-CoV-2 evolution during treatment of chronic infection

Steven A. Kemp et al.

Summary: Chronic infection with SARS-CoV-2 can lead to viral evolution and increased resistance to neutralizing antibodies in immunosuppressed individuals treated with convalescent plasma. During convalescent plasma therapy, there were significant shifts in the viral population structure and sensitivity, suggesting strong selection pressure on the virus during treatment.

NATURE (2021)

Add to Collection

Article Hematology

Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma

Irati Ormazabal Velez et al.

Summary: The use of convalescent plasma therapy in lymphoma patients with low gammaglobulin levels showed effectiveness in treating relapsed COVID-19, leading to clinical improvement and reducing the risk of virus relapse.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies

Preethi Jeyaraman et al.

Summary: This retrospective multicentre study analyzed the 14-day mortality in 33 patients with hematological malignancies who received convalescent plasma therapy for severe Covid-19. The study found that patients who received plasma therapy early had a shorter duration of hospitalization. The overall mortality rate was 45.5%, with no significant impact of disease status, active therapy, or comorbidities on mortality.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Virology

Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19

Monika Maria Biernat et al.

Summary: The use of convalescent plasma in patients with hematological malignancies and COVID-19 can improve overall survival, reduce the severity of infection, and accelerate recovery.

VIRUSES-BASEL (2021)

Add to Collection

Review Microbiology

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19

Arturo Casadevall et al.

Summary: Antibody therapies like convalescent plasma and monoclonal antibodies have emerged as potential treatments for COVID-19, following the principles of specificity, temporality, and quantity in administering specific antibodies early in the disease course. Historical lessons suggest that antibody therapy is most effective when used early in respiratory diseases.

MBIO (2021)

Add to Collection

Article Allergy

Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma

Luciana C. Ribeiro et al.

Summary: This case report highlights the potential of using COVID-19 convalescent donor plasma as a valuable therapeutic approach for patients with common variable immunodeficiency and severe COVID-19. The patient showed rapid improvement after receiving four doses of convalescent plasma over a period of 6 days, with reduction of lung abnormalities and interruption of mechanical ventilation.

ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Microbiology

Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy

Yusri Taha et al.

Summary: Two cases of persistent SARS-CoV-2 infection were successfully cleared with the monoclonal antibody combination casirivimab and imdevimab (REGN-COV2), highlighting the potential benefit of REGN-COV2 therapy for antibody deficient individuals. Further clinical studies are warranted to assess the effectiveness of REGN-COV2 in this patient population, especially in the context of emerging variants of concern like Omicron.

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS (2021)

Add to Collection

Article Hematology

COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?

D. Rnjak et al.

Summary: This study demonstrated the beneficial impact of passive immunotherapy with convalescent plasma in treating a prolonged, active COVID-19 infection in patients with hematological malignancies. Quantification of SARS-CoV2 neutralizing antibodies and immunophenotyping analysis revealed the correlation between transfused neutralizing antibodies and disease progression control, as well as the deficiency of the patient's humoral immune system and decreased levels of lymphocyte subpopulations.

TRANSFUSION CLINIQUE ET BIOLOGIQUE (2021)

Add to Collection

Article Immunology

Successful Management of COVID-19 Infection in 2 Early Post-Liver Transplant Recipients

Miles Dale et al.

Summary: COVID-19 has had a significant impact on global public health, especially on patients with organ transplants. The mortality rate of liver transplant patients with COVID-19 does not seem to be significantly higher than non-transplant patients. Management of post-liver transplant patients with COVID-19 infection is complex and requires further research for optimal treatment strategies.

TRANSPLANTATION PROCEEDINGS (2021)

Add to Collection

Article Urology & Nephrology

COVID-19 Infection Clinical Profile, Management, Outcome, and Antibody Response in Kidney Transplant Recipients: A Single Centre Experience

Sanjiv Jasuja et al.

Summary: Study on kidney transplant recipients with COVID-19 showed that patients needing ICU care, dialysis, and ventilation support had poor outcomes, while recovered patients mounted adequate antibody response.

INTERNATIONAL JOURNAL OF NEPHROLOGY (2021)

Add to Collection

Article Immunology

Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure

Verena Keitel et al.

Summary: In this study, the unique disease course and cure of SARS-CoV-2 infection in a patient with SCID and graft failure were described. It was found that viral clearance was only achieved after transfusion of convalescent plasma in the absence of a humoral immune response, highlighting the necessity of the humoral immune response for SARS-CoV-2 clearance.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery

Aurelia Zimmerli et al.

Summary: In this case report, convalescent plasma treatment of an immunosuppressed patient with COVID-19 showed positive effects, including rapid symptom relief, gradual viral clearance, and eventual full recovery. This indicates the potential value of convalescent plasma in treating immunosuppressed COVID-19 patients.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series

Thao T. Truong et al.

Summary: The study highlights the concern that persistent infection of SARS-CoV-2 in immunocompromised hosts may lead to mutation accumulation and emergence of strains that evade immune responses. There is a need to reassess infection control precautions and consider routine surveillance of mutations for their potential impact on viral transmission and immune escape.

EBIOMEDICINE (2021)

Add to Collection

Article Immunology

The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study

Chiara Sepulcri et al.

Summary: Immunocompromised patients can have prolonged shedding of SARS-CoV-2 and clinical relapses of COVID-19, with differences in cell immune dynamics and absence of virus-specific antibodies detected.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Review Biology

The Three Pillars of COVID-19 Convalescent Plasma Therapy

Massimo Franchini et al.

Summary: In this narrative review, the critical analysis focuses on three factors, known as pillars, crucial in determining the clinical effectiveness of this biologic therapy: convalescent plasma, the disease COVID-19, and the patients.

LIFE-BASEL (2021)

Add to Collection

Letter Oncology

Bamlanivimab plus etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

F. Pommeret et al.

ANNALS OF ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Undetectable SARS-CoV-2 active adaptive immunity-post-vaccination or post-COVID-19 severe disease-after immunosuppressants use

Oluwafeyi Adedoyin et al.

Summary: This study demonstrates the challenges of treating immunosuppressed patients with COVID-19 pneumonia, showing cases of undetectable adaptive immunity even after vaccination or infection, and the need for specialized monitoring and treatment methods.

BMJ CASE REPORTS (2021)

Add to Collection

Article Medicine, General & Internal

Complicated and persistent severe COVID-19 pneumonia in a recipient of allogeneic haematopoietic stem cell transplant

Lorenzo Lazzari et al.

Summary: This case report demonstrates the typical clinical course of COVID-19 in severely immunosuppressed patients and emphasizes the importance of prompt treatment directed towards viral clearance to compensate for the absence of valid immune reactivity in this population.

BMJ CASE REPORTS (2021)

Add to Collection

Article Infectious Diseases

Hyperimmune plasma in three immuno-deficient patients affected by non-severe, prolonged COVID-19: a single-center experience

Maria Grazia Cusi et al.

Summary: Despite encouraging initial data, there is currently no strong evidence supporting the use of CP and HP to treat COVID-19. In this limited experience, a good safety and efficacy of HP was found in 3 immunodeficient subjects. Further data are needed to assess whether this subtype of patients may particularly benefit from passive immunization.

BMC INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Ariel Kenig et al.

Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Oncology

Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy

Anna Furlan et al.

Summary: Four NHL patients with SARS-CoV-2 pneumonia after rituximab therapy showed early relapse and prolonged disease course despite initial treatment with remdesivir and steroids, but had rapid and significant response to convalescent hyperimmune plasma and extended course of remdesivir. These clinical observations suggest that the immunological effects of rituximab treatment in NHL patients should be considered for proper choice of SARS-CoV-2 laboratory tests and guiding therapeutic approaches.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery

Maamoun Basheer et al.

Summary: This case report presents a patient who had difficulty eradicating the corona virus due to being treated with Rituximab, but the combined use of external anti-viral agents like convalescent plasma successfully helped the patient's immune system to eradicate the virus.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Review Mycology

Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - Case report and review of literature

Akshay Khatri et al.

Summary: This case report describes a rare occurrence of mucormycosis following COVID-19 in a heart transplant recipient, highlighting the potential mechanisms by which COVID-19 may predispose individuals to invasive fungal infections. Despite aggressive therapeutic measures, the patient ultimately succumbed to the infection. The study also emphasizes the need for clinicians to be vigilant in evaluating for invasive fungal infections like mucormycosis in patients with COVID-19.

JOURNAL DE MYCOLOGIE MEDICALE (2021)

Add to Collection

Letter Medicine, General & Internal

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness

Aziz Sheikh et al.

LANCET (2021)

Add to Collection

Article Oncology

COVID-19 among patients with hematological malignancies: a national Israeli retrospective analysis with special emphasis on treatment and outcome

Ilana Levy et al.

Summary: This study found that COVID-19 infection is particularly severe in patients with hematological malignancies. Factors like age over 70, hypertension, and active hematological cancer treatment may increase the risk of severe disease or hospitalization, while remdesivir stands out as the most effective treatment among those examined.

LEUKEMIA & LYMPHOMA (2021)

Add to Collection

Review Rheumatology

COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review

Alicia Rodriguez-Pla et al.

Summary: A 77-year-old man with GPA on rituximab presented with worsening cough and shortness of breath after testing positive for SARS-CoV-2. Although nasal swab PCR testing was negative, bronchioloalveolar lavage PCR was positive. The patient did not develop antibodies but recovered quickly with medication.

RHEUMATOLOGY INTERNATIONAL (2021)

Add to Collection

Article Hematology

Convalescent plasma therapy in B-cell-depleted and B-cell sufficient patients with life-threatening COVID-19-A case series

Johanna Erber et al.

Summary: Convalescent plasma therapy may have different effects on patients with COVID-19 based on their B-cell status, with potential benefits seen in B-cell-depleted patients. D-dimer levels increased in all patients post-treatment, with control group patients experiencing more adverse reactions compared to B-cell-depleted patients.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Letter Immunology

Convalescent plasma treatment for early post-kidney transplant acquired COVID-19

Malte A. Kluger et al.

TRANSPLANT INFECTIOUS DISEASE (2021)

Add to Collection

Article Immunology

Case Report: Convalescent Plasma Therapy Induced Anti-SARS-CoV-2 T Cell Expansion, NK Cell Maturation and Virus Clearance in a B Cell Deficient Patient After CD19 CAR T Cell Therapy

Berislav Bosnjak et al.

Summary: The case study described a B cell-deficient patient with COVID-19 after receiving CD19 CAR-T cell therapy. Convalescent plasma therapy correlated with virus clearance in the patient. The findings suggest that convalescent plasma therapy can activate cellular immune responses to clear SARS-CoV-2 infections, which could be important for the treatment of COVID-19 patients if further confirmed in larger clinical studies.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Pediatrics

Case Report: Remdesivir and Convalescent Plasma in a Newly Acute B Lymphoblastic Leukemia Diagnosis With Concomitant Sars-CoV-2 Infection

Giovanni Battista Dell'Isola et al.

Summary: The use of Remdesivir and Convalescent Plasma in a pediatric ALL patient with concurrent SARS-CoV-2 infection led to rapid resolution of the infection without any adverse events. This treatment approach could be beneficial in accelerating infection resolution and safely initiating immunosuppressive treatment in patients with malignancies, although further studies are needed to confirm its efficacy.

FRONTIERS IN PEDIATRICS (2021)

Add to Collection

Article Microbiology

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment

Liang Chen et al.

Summary: The study documented the microevolution of SARS-CoV-2 in an immunosuppressed patient undergoing steroid and convalescent plasma therapy, showing multiple NTD and RBD mutations. This suggests that immunocompromised patients may serve as breeding grounds for immune escape mutants, highlighting the need for enhanced measures to reduce transmission.

MSPHERE (2021)

Add to Collection

Article Oncology

Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19

Michael A. Thompson et al.

Summary: This study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19. Results showed that convalescent plasma treatment was associated with improved 30-day mortality, especially in patients requiring intensive care unit admission or mechanical ventilatory support.

JAMA ONCOLOGY (2021)

Add to Collection

Article Immunology

Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Host Displaying Treatment Induced Viral Evolution

Ida Monrad et al.

Summary: This case demonstrates that immunocompromised patients may continue to carry the virus beyond the acute phase of infection, even asymptomatically. Moreover, viral sequencing revealed major changes in the spike protein over time, potentially associated with convalescent plasma treatment.

OPEN FORUM INFECTIOUS DISEASES (2021)

Add to Collection

Review Medicine, General & Internal

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews

Massimo Franchini et al.

Summary: This study aimed to summarize evidence on the efficacy and safety of convalescent plasma (CP) in treating COVID-19. Results showed a reduction in mortality with CP over standard therapy when administered early and at high titer, without increased adverse reactions, although there was variability in the certainty of the evidence.

DIAGNOSTICS (2021)

Add to Collection

Article Medicine, Research & Experimental

A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia

Katharine J. Bar et al.

Summary: This study assessed the efficacy of CCP in severely ill, hospitalized adults with COVID-19 pneumonia, showing significant benefits in clinical severity score and 28-day mortality. The results suggest that CCP may benefit select populations, especially those with comorbidities who are treated early.

JOURNAL OF CLINICAL INVESTIGATION (2021)

Add to Collection

Article Infectious Diseases

Convalescent Plasma in a Patient with Protracted COVID-19 and Secondary Hypogammaglobulinemia Due to Chronic Lymphocytic Leukemia: Buying Time to Develop Immunity?

Jaap L. J. Hanssen et al.

Summary: This study examined the immunological responses of a patient with chronic lymphocytic leukemia and hypogammaglobulinemia who received treatment with COVID-19 convalescent plasma (CCP). It was found that some serological tests for COVID-19 may not be suitable for monitoring levels of neutralizing antibodies after CCP treatment. In retrospect, it is believed that CCP gave the patient time to develop an adequate cellular immune response, leading to viral clearance and clinical recovery.

INFECTIOUS DISEASE REPORTS (2021)

Add to Collection

Article Immunology

Recovery From COVID-19 Pneumonia in a Heart Transplant Recipient A Case Report

A. Bakhsh et al.

Summary: This case study illustrates a successful recovery of a 54-year-old female solid-organ transplant recipient with severe COVID-19 pneumonia through multidisciplinary team management and individualized care plan. Solid-organ transplant recipients are at high risk for COVID-19 infection and require personalized treatment strategies for optimal outcomes.

INFECTIOUS DISEASES IN CLINICAL PRACTICE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Cardiac transplant recipient with COVID-19 induced acute hypoxic respiratory failure: a case report

Ariyon Schreiber et al.

Summary: This case report demonstrates that adjusting immunosuppressant medications in cardiac transplant recipients according to recommendations by the International Society of Heart and Lung Transplantation can be safe and effective. Certain aspects of the current literature on COVID-19 management can be extrapolated to cardiac transplant recipients safely. Providing supportive care with dexamethasone, remdesivir, and convalescent plasma may benefit cardiac transplant recipients, although there is conflicting evidence in the current literature regarding convalescent plasma and remdesivir.

EUROPEAN HEART JOURNAL-CASE REPORTS (2021)

Add to Collection

Article Immunology

Incidence and Outcomes of COVID-19 in Kidney and Liver Transplant Recipients With HIV: Report From the National HOPE in Action Consortium

Sapna A. Mehta et al.

Summary: Among kidney and liver transplant recipients with HIV, there was a 4% incidence rate of COVID-19 with high mortality. Most patients required hospitalization and aggressive treatment with high-dose steroids, tocilizumab, remdesivir, and convalescent plasma.

TRANSPLANTATION (2021)

Add to Collection

Article Medicine, General & Internal

A Case of COVID-19 Re-Infection in a Liver Transplant Patient

Michael Mohseni et al.

Summary: This case report describes a rare scenario of presumed COVID-19 re-infection in a liver transplant patient who experienced mild symptoms. The patient was treated in the Emergency Department and recovered with outpatient follow-up. Immunosuppression may provide some protection from the initial disease process in COVID-19, but could also increase the risk of re-infection due to decreased humoral immunity.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Hematology

SARS-CoV-2 convalescent plasma therapy in pediatric patient after hematopoietic stem cell transplantation

Dmitry Balashov et al.

Summary: A 9-month-old girl with juvenile myelomonocytic leukemia who received HSCT from a haploidentical donor developed bilateral viral pneumonia due to SARS-CoV-2 infection, which was partially resolved with tocilizumab and convalescent plasma therapy. However, complete elimination of the virus was not achieved after 4 months, likely due to persistent immunodeficiency and lack of adaptive immune response post-HSCT. This case highlights the potential effectiveness of convalescent plasma in combination with other therapies for treating COVID-19 in immunocompromised patients.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Infectious Diseases

COVID-19 Coinfection with Mycobacterium abscessus in a Patient with Multiple Myeloma

Jose A. Rodriguez et al.

Summary: This case report underscores the importance of maintaining a broad differential diagnosis and considering multiple coinfections, including atypical ones during the COVID-19 pandemic, such as the co-infection of SARS-CoV-2 and Mycobacterium abscessus discussed above, in order to provide goal-directed therapy.

CASE REPORTS IN INFECTIOUS DISEASES (2021)

Add to Collection

Article Cell Biology

Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency

Kazuhito Honjo et al.

Summary: Convalescent plasma (CP) has beneficial effects in severely ill COVID-19 patients, even when administered relatively late in the disease course. However, there are widely varying neutralizing antibody (NAbs) titers within different CP units, highlighting the importance of determining neutralizing activity for maximizing therapeutic benefits.

CELL REPORTS MEDICINE (2021)

Add to Collection

Article Cell & Tissue Engineering

Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient

Tali-Anne Szwebel et al.

Summary: A HIV-1-infected patient with chronic COVID-19 was treated with anti-CD20 monoclonal antibody for B-cell lymphoma, but the treatment's viral efficacy was confirmed to be poor through monitoring plasma SARS-CoV-2 RNA by ddPCR. The patient's complete recovery after COVID-19 convalescent plasmatherapy was closely associated with clearance of plasma SARS-CoV-2 RNA.

STEM CELL REVIEWS AND REPORTS (2021)

Add to Collection

Article Public, Environmental & Occupational Health

The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?

Noah C. Peeri et al.

INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2020)

Add to Collection

Editorial Material Medicine, Research & Experimental

The convalescent sera option for containing COVID-19

Arturo Casadevall et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Hematology

Convalescent (immune) plasma treatment in a myelodysplastic COVID-19 patient with disseminated tuberculosis

Olgu Erkin Cinar et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

News Item Medicine, General & Internal

Covid-19: WHO declares pandemic because of alarming levels of spread, severity, and inaction

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Letter Biophysics

COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasma

Alex Niu et al.

BONE MARROW TRANSPLANTATION (2020)

Add to Collection

Letter Allergy

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

Estefania Mira et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Oncology

A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward

Bo Wang et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Infectious Diseases

A minimal common outcome measure set for COVID-19 clinical research

J. C. Marshall et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Letter Oncology

Response to COVID-19 in persons with haematological cancers

Stefan Hatzl et al.

LEUKEMIA (2020)

Add to Collection

Article Hematology

Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19

Thomas Hueso et al.

BLOOD (2020)

Add to Collection

Letter Urology & Nephrology

Outcomes of COVID-19 positive kidney transplant recipients: A single-center experience

Goni Katz-Greenberg et al.

CLINICAL NEPHROLOGY (2020)

Add to Collection

Article Hematology

Prolonged viral shedding in a lymphoma patient with COVID-19 infection receiving convalescent plasma

Ayse Karatas et al.

TRANSFUSION AND APHERESIS SCIENCE (2020)

Add to Collection

Letter Oncology

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia

Guido Lancman et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)

Add to Collection

Article Immunology

Coronavirus Disease 2019 Viremia, Serologies, and Clinical Course in a Case Series of Transplant Recipients

Johanna Christensen et al.

TRANSPLANTATION PROCEEDINGS (2020)

Add to Collection

Letter Allergy

Three patients with X-linked agammaglobulinemia hospitalized for COVID-19 improved with convalescent plasma

Haoli Jin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Article Hematology

Successful transfer of anti-SARS-CoV-2 immunity using convalescent plasma in an MM patient with hypogammaglobulinemia and COVID-19

Tim Luetkens et al.

BLOOD ADVANCES (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer

Victoria A. Avanzato et al.

CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

Matthew S. Buckland et al.

NATURE COMMUNICATIONS (2020)

Add to Collection

Article Infectious Diseases

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

Ivana Milosevic et al.

JOURNAL OF INFECTION IN DEVELOPING COUNTRIES (2020)

Add to Collection

Article Medicine, General & Internal

A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma

Joanna L. Moore et al.

AMERICAN JOURNAL OF CASE REPORTS (2020)

Add to Collection

Article Infectious Diseases

Early use of tocilizumab in respiratory failure associated with acute COVID -19 pneumonia in recipients with solid organ transplantation

Suresh J. Antony et al.

IDCASES (2020)

Add to Collection

Article Medicine, General & Internal

Successful recovery of COVID-19-associated recurrent diarrhea and gastrointestinal hemorrhage using convalescent plasma

Li-Bo Zhang et al.

MILITARY MEDICAL RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Concurrent Diagnosis of Acute Myeloid Leukemia and COVID-19: A Management Challenge

Abdul Moiz Khan et al.

CUREUS JOURNAL OF MEDICAL SCIENCE (2020)

Add to Collection

Article Gastroenterology & Hepatology

COVID-19 in Liver Transplant Recipients - A Series with Successful Recovery

Ashok Choudhury et al.

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2019)

Add to Collection

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

Add to Collection

Article Medicine, General & Internal

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2016)

Add to Collection

Editorial Material Medicine, General & Internal

GRADE:: what is quality of evidence and why is it important to clinicians?

Gordon H. Guyatt et al.

BMJ-BRITISH MEDICAL JOURNAL (2008)

Add to Collection

Article Medicine, General & Internal

Measuring inconsistency in meta-analyses

JPT Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.